Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cyclic Peptidyl Inhibitors against CAL/CFTR Interaction for Treatment of Cystic Fibrosis.

Journal of medicinal chemistry - 24 Dec 2020

Dougherty Patrick G, Wellmerling Jack H, Koley Amritendu, Lukowski Jessica K, Hummon Amanda B, Cormet-Boyaka Estelle, Pei Dehua

Abstract excerpt

Cystic fibrosis (CF) is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, encoding for a chloride ion channel. Membrane expression of CFTR is negatively regulated by CFTR-associated ligand (CAL). We previously showed that inhibition of the CFTR/CAL interaction with a cell-permeable peptide improves the function of rescued F508del-CFTR. In this study, optimization of the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cystic Fibrosis Transmembrane Conductance Regulator
Share to Drug Stability

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Molecular Docking Simulation

Share to PDZ Domains

Share to Peptides, Cyclic

Share to Permeability

Share to Phosphoproteins

Share to Sodium-Hydrogen Exchangers

Source

Open in PubMed Open full text

Identifiers

PMID: 33314931
DOI: 10.1021/acs.jmedchem.0c01528
PMCID: PMC8011814

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cyclic Peptidyl Inhibitors against CAL/CFTR Interaction for Treatment of Cystic Fibrosis.PMID 33314931Read ↗

Computational Design of a PDZ Domain Peptide Inhibitor that Rescues CFTR ActivitySemantic proximity Read ↗

Peptide CIGB-552 has a synergistic effect on CFTR-F508del combined with Elexacaftor/Tezacaftor/IvacaftorSemantic proximity Read ↗

PDZ Structure and Implication in Selective Drug Design against Cystic Fibrosis.Semantic proximity Read ↗

CFTR inhibitors.Semantic proximity Read ↗

Complementary Dual Approach for In Silico Target Identification of Potential Pharmaceutical Compounds in Cystic Fibrosis.Semantic proximity Read ↗

Current development of CFTR potentiators in the last decade.Semantic proximity Read ↗

Targeting CAL as a Negative Regulator of ΔF508-CFTR Cell-Surface ExpressionSemantic proximity Read ↗

Discovery of GLPG2737, a Potent Type 2 Corrector of CFTR for the Treatment of Cystic Fibrosis in Combination with a Potentiator and a Type 1 Co-corrector.Semantic proximity Read ↗

CFTR chloride channel drug discovery--inhibitors as antidiarrheals and activators for therapy of cystic fibrosis.Semantic proximity Read ↗

Discovery of GLPG2451, a Novel Once Daily Potentiator for the Treatment of Cystic FibrosisSemantic proximity Read ↗

New insights into structure and function of bis-phosphinic acid derivatives and implications for CFTR modulation.Semantic proximity Read ↗

Inhibition of the QPCT-PDIA4 axis rescues ΔF508 and N1303K CFTR in cystic fibrosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.